Adjuvant Concurrent Chemoradiotherapy in Extrahepatic Cholangiocarcinoma

August 2020, Vol 1, No 1

Treatment with 6 months of adjuvant capecitabine chemotherapy is currently the standard of care in patients with resected extrahepatic cholangiocarcinoma (CCA).1 However, the benefit of treatment with adjuvant radiation therapy is not well-defined.

Using data from the National Cancer Database, a study presented at the 2020 ASCO annual meeting evaluated survival outcomes with adjuvant chemoradiotherapy compared with chemotherapy alone in patients with extrahepatic CCA.2 The study was led by Walid L. Shaib, MD, Medical Oncologist, Winship Cancer Institute of Emory University, Atlanta, GA.

Patients who had resected stage I to stage III extrahepatic CCA between 2004 and 2013 were identified from the National Cancer Database. Patients who had received neoadjuvant therapy were excluded from this analysis. Univariate and multivariable analyses were conducted, and Kaplan-Meier curves were used to compare the overall survival (OS) of the patients based on the treatment received.

The investigators identified 236 patients with extrahepatic CCA, including 68 (28.8%) patients with stage I disease, 134 (56.8%) with stage II disease, and 34 (14.4%) with stage III disease.

A total of 89 (37.7%) patients received adjuvant chemotherapy and 147 (62.3%) patients received adjuvant chemoradiotherapy. The median dose of radiation was 50.4 Gy. Adjuvant chemoradiotherapy was predominantly used in patients with regional node-positive disease (P = .016) and in patients with negative surgical margins (P = .002).

The use of adjuvant chemoradiotherapy was associated with improved OS compared with chemotherapy alone in univariate (hazard ratio, 0.64; P = .019) and multivariable (hazard ratio, 0.65; P = .030) analyses. The median OS was 33.8 months and the 1-year OS rate was 87.7% for patients who received chemoradiotherapy compared with 23.8 months and 75.5%, respectively, in patients who received chemotherapy alone.

The investigators concluded that adjuvant chemoradiotherapy was associated with improved survival in patients with resected extrahepatic CCA compared with chemotherapy alone.

References

  1. Primrose JN, Fox RP, Palmer DH, et al; for the BILCAP study group. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019;20:663-673. Erratum in: Lancet Oncol. 2019;20:e242.
  2. Shaib WL, Zakka KM, Tian F, et al. Adjuvant concurrent chemoradiotherapy in extrahepatic cholangiocarcinoma. J Clin Oncol. 2020;38(15_suppl):Abstract 4583.

Related Items

HRQOL in Patients With Advanced BTC Who Received Pembrolizumab With GemCis in the KEYNOTE-966 study
September 2023, Vol 4, No 3
Researchers explore the impact of gemcitabine/cisplatin plus pembrolizumab on patient health-related quality of life in a subanalysis of the KEYNOTE-966 study.
Durvalumab Plus Tremelimumab With or Without Capecitabine in BTC: The ADJUBIL Study
September 2023, Vol 4, No 3
Researchers in the ADJUBIL study plan to assess the clinical activity of the immunotherapies durvalumab and tremelimumab with or without capecitabine in patients with resectable biliary tract cancer in the adjuvant setting.
SGNTUC-019: A Phase 2 Study of Tucatinib and Trastuzumab in Patients With Previously Treated HER2-Positive Metastatic BTC
September 2023, Vol 4, No 3
Basket study investigated targeted therapies as second-line treatment for patients with biliary tract cancer who are HER2-positive.
Rucaparib and Nivolumab as Maintenance Therapy Following Chemotherapy in Patients With Advanced BTC: BilT-02
September 2023, Vol 4, No 3
Researchers are investigating novel combination therapies, including immunotherapies and poly-ADP ribose polymerase (PARP) inhibitors, to improve survival in patients with biliary tract cancer; here, the BilT-02 study is summarized.
Results From HERIZON-BTC-01: Zanidatamab in Previously Treated HER2-Amplified BTC
September 2023, Vol 4, No 3
Preliminary results from the phase 2b HERIZON-BTC-01 study investigating the efficacy of zanidatamab in patients with HER2-positive biliary tract cancer are presented.
Using ctDNA as a Predictive Biomarker in Patients With CCA: Subanalysis of the STAMP Trial
September 2023, Vol 4, No 3
A subanalysis of the STAMP trial examines the clinical impact of using circulating tumor DNA for detecting molecular residual disease and monitoring in patients with CCA in the adjuvant setting.
BILCAP Investigators Explore Alterations in Cancer Driver Genes and Other Mutations in Patients With BTC
September 2023, Vol 4, No 3
The researchers found that EGFR amplifications and FGFR3 fusions may be important predictive biomarkers in biliary tract cancer (BTC) and may serve as a future target for systemic anticancer therapy in patients with BTC.
Using Liquid Biopsy to Detect FGFR2 and Other Actionable Rearrangements in Patients With GI Cancer
September 2023, Vol 4, No 3
Pashtoon Kasi, MD, MS, presented results of a study exploring the utility of circulating tumor DNA–based comprehensive genomic profiling to detect actionable rearrangements in patients with gastrointestinal malignancies.
CCA Summit Live from ASCO 2023
By Renuka V. Iyer, MD; Vaibhav Sahai, MBBS, MS
Videos
On June 4, 2023, we presented an overview of key abstracts on cholangiocarcinoma (CCA) presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO).
GemCis with or without CPI-613 as First-Line Therapy for Patients with Advanced BTCs: The BilT-04 Study
September 2022, Vol 3, No 3
Patients with advanced biliary tract cancers (BTCs) have a poor prognosis despite systemic chemotherapy. Gemcitabine/cisplatin (GemCis) is the standard first-line systemic therapy for BTCs; however, median overall survival was only 11.7 months.

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: